{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:28:50Z","timestamp":1791181730386,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,9,22]],"date-time":"2010-09-22T00:00:00Z","timestamp":1285113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2010,9,22]],"date-time":"2010-09-22T00:00:00Z","timestamp":1285113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s10637-010-9541-0","type":"journal-article","created":{"date-parts":[[2010,9,21]],"date-time":"2010-09-21T01:53:25Z","timestamp":1285034005000},"page":"695-701","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors"],"prefix":"10.1007","volume":"30","author":[{"given":"Matthew D.","family":"Galsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Von Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasir","family":"Nagarwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine M.","family":"Mahoney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Midwinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Vocila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal Z.","family":"Zaks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,22]]},"reference":[{"key":"9541_CR1","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrc1124","volume":"3","author":"AW Millar","year":"2003","unstructured":"Millar AW, Lynch KP (2003) Rethinking clinical trials for cytostatic drugs. Nat Rev 3:540\u2013545","journal-title":"Nat Rev"},{"key":"9541_CR2","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10549-007-9885-0","volume":"112","author":"D Cameron","year":"2008","unstructured":"Cameron D, Casey M, Press M et al (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112:533\u2013543","journal-title":"Breast Cancer Res Treat"},{"key":"9541_CR3","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733\u20132743","journal-title":"N Engl J Med"},{"key":"9541_CR4","doi-asserted-by":"publisher","first-page":"7861","DOI":"10.1158\/1078-0432.CCR-08-1056","volume":"14","author":"MF Press","year":"2008","unstructured":"Press MF, Finn RS, Cameron D et al (2008) HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res 14:7861\u20137870","journal-title":"Clin Cancer Res"},{"key":"9541_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1136\/jcp.48.2.129","volume":"48","author":"RH Hardwick","year":"1995","unstructured":"Hardwick RH, Shepherd NA, Moorghen M, Newcomb PV, Alderson D (1995) c-erbB-2 overexpression in the dysplasia\/carcinoma sequence of Barrett\u2019s oesophagus. J Clin Pathol 48:129\u2013132","journal-title":"J Clin Pathol"},{"key":"9541_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0090-8258(92)90103-P","volume":"47","author":"DJ Hetzel","year":"1992","unstructured":"Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS, Podratz KC (1992) HER-2\/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 47:179\u2013185","journal-title":"Gynecol Oncol"},{"key":"9541_CR7","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1002\/cncr.10526","volume":"94","author":"PN Lara Jr","year":"2002","unstructured":"Lara PN Jr, Meyers FJ, Gray CR et al (2002) HER-2\/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial. Cancer 94:2584\u20132589","journal-title":"Cancer"},{"key":"9541_CR8","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0090-4295(99)00604-4","volume":"55","author":"H Miyamoto","year":"2000","unstructured":"Miyamoto H, Kubota Y, Noguchi S et al (2000) C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer. Urology 55:679\u2013683","journal-title":"Urology"},{"key":"9541_CR9","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s10620-005-9057-1","volume":"51","author":"DI Park","year":"2006","unstructured":"Park DI, Yun JW, Park JH et al (2006) HER-2\/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 51:1371\u20131379","journal-title":"Dig Dis Sci"},{"key":"9541_CR10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/sj.bjc.6605448","volume":"102","author":"K El-Sahwi","year":"2010","unstructured":"El-Sahwi K, Bellone S, Cocco E et al (2010) In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer 102:134\u2013143","journal-title":"Br J Cancer"},{"key":"9541_CR11","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1200\/JCO.2005.05.4221","volume":"24","author":"MS Gordon","year":"2006","unstructured":"Gordon MS, Matei D, Aghajanian C et al (2006) Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 24:4324\u20134332","journal-title":"J Clin Oncol"},{"key":"9541_CR12","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1200\/JCO.2006.08.0994","volume":"25","author":"MH Hussain","year":"2007","unstructured":"Hussain MH, MacVicar GR, Petrylak DP et al (2007) Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2\/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 25:2218\u20132224","journal-title":"J Clin Oncol"},{"key":"9541_CR13","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.canlet.2008.07.018","volume":"272","author":"JW Kim","year":"2008","unstructured":"Kim JW, Kim HP, Im SA et al (2008) The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett 272:296\u2013306","journal-title":"Cancer Lett"},{"key":"9541_CR14","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/sj.bjc.6604278","volume":"98","author":"GE Konecny","year":"2008","unstructured":"Konecny GE, Venkatesan N, Yang G et al (2008) Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer 98:1076\u20131084","journal-title":"Br J Cancer"},{"key":"9541_CR15","doi-asserted-by":"crossref","unstructured":"Van Cutsem E, Kang Y, Chung H et al (2009) Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer. Proc Am Soc Clin Oncol 27","DOI":"10.1200\/jco.2009.27.15_suppl.lba4509"},{"key":"9541_CR16","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1158\/1078-0432.CCR-09-1112","volume":"16","author":"ZA Wainberg","year":"2010","unstructured":"Wainberg ZA, Anghel A, Desai AJ et al (2010) Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 16:1509\u20131519","journal-title":"Clin Cancer Res"},{"key":"9541_CR17","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1002\/cncr.24337","volume":"115","author":"C Wulfing","year":"2009","unstructured":"Wulfing C, Machiels JP, Richel DJ et al (2009) A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 115:2881\u20132890","journal-title":"Cancer"},{"key":"9541_CR18","doi-asserted-by":"crossref","unstructured":"Galsky MD, Zaks T, Hassani H et al (2009) Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics. Invest New Drugs","DOI":"10.1007\/s10637-009-9239-3"},{"key":"9541_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"9541_CR20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10637-006-9020-9","volume":"25","author":"MD Galsky","year":"2007","unstructured":"Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin DF (2007) Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Investig New Drugs 25:265\u2013270","journal-title":"Investig New Drugs"},{"key":"9541_CR21","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1080\/07357900600705268","volume":"24","author":"MH Kulke","year":"2006","unstructured":"Kulke MH, Muzikansky A, Clark J et al (2006) A phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma. Cancer Investig 24:346\u2013350","journal-title":"Cancer Investig"},{"key":"9541_CR22","doi-asserted-by":"publisher","first-page":"5937","DOI":"10.1158\/1078-0432.CCR-08-3282","volume":"15","author":"PP Peethambaram","year":"2009","unstructured":"Peethambaram PP, Melisko ME, Rinn KJ et al (2009) A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2\/neu. Clin Cancer Res 15:5937\u20135944","journal-title":"Clin Cancer Res"},{"key":"9541_CR23","first-page":"4902","volume":"58","author":"TZ Zaks","year":"1998","unstructured":"Zaks TZ, Rosenberg SA (1998) Immunization with a peptide epitope (p369\u2013377) from HER-2\/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2\/neu+ tumors. Cancer Res 58:4902\u20134908","journal-title":"Cancer Res"},{"key":"9541_CR24","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","volume":"26","author":"RG Amado","year":"2008","unstructured":"Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626\u20131634","journal-title":"J Clin Oncol"},{"key":"9541_CR25","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1056\/NEJMoa051918","volume":"353","author":"IK Mellinghoff","year":"2005","unstructured":"Mellinghoff IK, Wang MY, Vivanco I et al (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012\u20132024","journal-title":"N Engl J Med"},{"key":"9541_CR26","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1593\/neo.09898","volume":"11","author":"DM Havaleshko","year":"2009","unstructured":"Havaleshko DM, Smith SC, Cho H et al (2009) Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer. Neoplasia (New York, NY) 11:1185\u20131193","journal-title":"Neoplasia (New York, NY)"},{"key":"9541_CR27","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","volume":"25","author":"AC Wolff","year":"2007","unstructured":"Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118\u2013145","journal-title":"J Clin Oncol"},{"key":"9541_CR28","first-page":"65","volume":"15","author":"T Yano","year":"2006","unstructured":"Yano T, Doi T, Ohtsu A et al (2006) Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 15:65\u201371","journal-title":"Oncol Rep"},{"key":"9541_CR29","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1093\/jnci\/93.15.1141","volume":"93","author":"R Simon","year":"2001","unstructured":"Simon R, Nocito A, Hubscher T et al (2001) Patterns of her-2\/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 93:1141\u20131146","journal-title":"J Natl Cancer Inst"},{"key":"9541_CR30","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/sj.bjc.6602738","volume":"93","author":"J Zidan","year":"2005","unstructured":"Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A (2005) Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 93:552\u2013556","journal-title":"Br J Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9541-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-010-9541-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9541-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9541-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:18:51Z","timestamp":1678558731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-010-9541-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,22]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["9541"],"URL":"https:\/\/doi.org\/10.1007\/s10637-010-9541-0","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,22]]},"assertion":[{"value":"14 July 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}